CHD2-Related CNS Pathologies
Marc-Michel Wilson1,2, David C Henshall1,2, Susan M Byrne2,3,4
1Department of Physiology and Medical Physics, RCSI, University of Medicine and Health Sciences, Dublin 02, Ireland.
Abstract:
Epileptic encephalopathies (EE) are severe epilepsy syndromes characterized by multiple seizure types, developmental delay and even regression. This class of disorders are increasingly being identified as resulting from de novo genetic mutations including many identified mutations in the family of chromodomain helicase DNA binding (CHD) proteins. In particular, several de novo pathogenic mutations have been identified in the gene encoding chromodomain helicase DNA binding protein 2 (CHD2), a member of the sucrose nonfermenting (SNF-2) protein family of epigenetic regulators. These mutations in the CHD2 gene are causative of early onset epileptic encephalopathy, abnormal brain function, and intellectual disability. Our understanding of the mechanisms by which modification or loss of CHD2 cause this condition remains poorly understood. Here, we review what is known and still to be elucidated as regards the structure and function of CHD2 and how its dysregulation leads to a highly variable range of phenotypic presentations.
Insights
Genetic mutations in CHD2 cause severe early-onset epileptic encephalopathies. This review explores CHD2
Area of Science:
- Genetics
- Neuroscience
- Epigenetics
Background:
- Epileptic encephalopathies (EE) are severe epilepsy syndromes with developmental delays.
- De novo genetic mutations, particularly in chromodomain helicase DNA binding (CHD) proteins, are increasingly linked to EE.
- Specific mutations in the CHD2 gene are causative of early-onset epileptic encephalopathy, intellectual disability, and abnormal brain function.
Purpose of the Study:
- To review the current understanding of Chromodomain Helicase DNA Binding Protein 2 (CHD2) structure and function.
- To elucidate the mechanisms by which CHD2 dysregulation leads to epileptic encephalopathies.
- To highlight the variability in phenotypic presentations associated with CHD2 mutations.
Main Methods:
- Literature review of studies on CHD2 mutations and epileptic encephalopathies.
- Analysis of the role of CHD2 as an epigenetic regulator in the sucrose nonfermenting (SNF-2) protein family.
- Examination of genotype-phenotype correlations in patients with CHD2-related disorders.
Main Results:
- Several de novo pathogenic mutations in the CHD2 gene have been identified.
- CHD2 mutations are associated with early-onset epileptic encephalopathy, intellectual disability, and abnormal brain function.
- The precise mechanisms linking CHD2 dysfunction to disease phenotypes are not fully understood.
Conclusions:
- CHD2 is a critical gene involved in neurodevelopment and epigenetic regulation.
- Dysregulation of CHD2 function contributes to a spectrum of epileptic encephalopathy phenotypes.
- Further research is needed to fully understand CHD2's role and develop targeted therapies.
Related Concept Videos
01:28Disorders of the Nervous Tissue
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
01:26Coronary Artery Disease II: Pathophysiology
01:15Parkinson's Disease: Overview